Treatment of low-risk myelodysplastic syndromes by erythroprotein and its derivatives

被引:0
|
作者
Villeval, Jean-Luc [1 ]
Sainty, Danielle [2 ]
机构
[1] Inst Gustave Roussy, Villejuif, France
[2] Inst Paoli Calmettes, Marseille, France
来源
HEMATOLOGIE | 2006年 / 12卷
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:10 / 11
页数:2
相关论文
共 50 条
  • [2] Amifostine in the treatment of low-risk myelodysplastic syndromes
    Grossi, A
    Fabbri, A
    Santini, V
    Leoni, F
    Nozzoli, C
    Longo, G
    Pagliai, G
    Ciolli, S
    Ferrini, PR
    HAEMATOLOGICA, 2000, 85 (04) : 367 - 371
  • [3] rHuEpo treatment in low-risk myelodysplastic syndromes
    Grossi, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 574 - 574
  • [4] Current treatment strategies in low-risk myelodysplastic syndromes
    Giagounidis, Aristoteles A. N.
    Germing, Ulrich
    Aul, Carlo
    CANCER TREATMENT REVIEWS, 2007, 33 : S19 - S24
  • [5] New aspects of the treatment of patients with low-risk myelodysplastic syndromes
    Hofmann, WK
    Seipelt, G
    Kalina, U
    Hoelzer, D
    ONKOLOGIE, 2000, 23 (01): : 12 - 16
  • [6] Low-risk myelodysplastic syndromes and iron overload
    Fenaux, Pierre
    HEMATOLOGIE, 2006, 12 : 9 - 9
  • [7] Supportive therapy for low-risk myelodysplastic syndromes
    Gay, Julie
    HEMATOLOGIE, 2008, 14 (03): : 178 - 184
  • [8] Erythropoietin for the anemia of low-risk myelodysplastic syndromes
    Fenaux, P
    Ades, L
    BLOOD, 2005, 106 (03) : 768 - 769
  • [9] Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
    Molica, Matteo
    Rossi, Marco
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (04) : 233 - 241
  • [10] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Fu, Alex Z.
    Maciejewski, Jaroslaw R.
    Golshayan, Ali-Reza
    Kalaycio, Matt E.
    Kaftan, Michael W.
    CANCER, 2007, 109 (06) : 1125 - 1132